Clavix - Clavix is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It is marketed by Bristol-Myers Squibb and Sanofi-Aventis under the trade name Plavix, by Sun Pharmaceuticals under the trade name Clopilet, by Ranbaxy Laboratories under the trade name Ceruvin, and under the name "Clavix" by Intas Pharmaceuticals. It works by irreversibly inhibiting a receptor called P2Y12. Adverse effects include hemorrhage.
Clavix is a blood-thinning medicine. It prevents special cells in the blood -- the platelets -- from sticking to each other. This reduces the risk of harmful blood clots forming. Blood clots that form in a blood vessel inside the heart or brain can cause a heart attack or a stroke. Clavix is used to reduce the risk of heart attacks and strokes in people at high risk. This includes people who have had a heart attack or stroke before and are at risk of getting another one. It also includes people with blood circulation problems that may increase their chances of getting a heart attack or stroke. Clavix is also used together with to prevent blood clots in people who have had stents inserted into their heart arteries. Clavix may also be used to treat other conditions such as peripheral arterial disease (where there is some blockage or narrowing of arteries) or heart disease.
Indications: Reduction of athero-sclerotic events (MI, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent MI or established peripheral arterial disease.
Active ingredients: Clopidogrel